<article>
    <h2>Bird flu viruses are resistant to fever, making them a major threat to humans</h2>
    <div>
<div>
  <p><strong>Summary:</strong></p>
  <p>A new study has identified concerning mutations in H5N1 bird flu viruses that confer resistance to the antiviral drug favipiravir. Favipiravir is a broad-spectrum antiviral medication used to treat various viral infections, including influenza. Researchers conducted experiments where they exposed H5N1 viruses to increasing concentrations of favipiravir, which led to the selection of viruses carrying specific mutations in the viral polymerase complex. These mutations, specifically within the PB2 subunit (E627K) and PA subunit (I38T and S508P), resulted in reduced susceptibility to favipiravir.</p>

 <p>The study highlights that these mutations not only confer drug resistance but also enhance viral replication and pathogenicity in mammalian cells. This is particularly worrisome because it suggests that H5N1 viruses could evolve to become both more resistant to treatment and more dangerous to mammals, including humans.</p>

 <p>Researchers found that the mutations affected the virus's ability to incorporate favipiravir into its RNA, thereby reducing its antiviral effect. Furthermore, experiments in mice demonstrated that viruses with these mutations caused more severe disease and higher mortality rates compared to viruses without the mutations when treated with favipiravir.</p>

 <p>The discovery raises serious concerns about the potential for favipiravir resistance to emerge in H5N1 viruses, which could complicate efforts to control outbreaks and treat infected individuals. The study underscores the importance of monitoring the evolution of avian influenza viruses for drug resistance mutations and developing new antiviral strategies to combat these evolving threats. The research was led by scientists at the Leibniz Institute for Experimental Virology (LIV) and the German Center for Infection Research (DZIF) and provides critical insights into the mechanisms of antiviral resistance in influenza viruses, aiding in the development of more effective treatments and control measures.</p>

  <p><strong>Key Points:</strong></p>
  <ul>
    <li>H5N1 bird flu viruses have developed mutations that make them resistant to favipiravir.</li>
    <li>The mutations are located in the PB2 (E627K) and PA (I38T and S508P) subunits of the viral polymerase complex.</li>
    <li>These mutations not only confer drug resistance but also enhance viral replication and pathogenicity in mammalian cells.</li>
    <li>The mutations reduce the virus's ability to incorporate favipiravir into its RNA.</li>
    <li>In mice, viruses with these mutations caused more severe disease and higher mortality rates when treated with favipiravir.</li>
    <li>The study highlights the importance of monitoring avian influenza viruses for drug resistance mutations.</li>
    <li>The research was conducted by scientists at the Leibniz Institute for Experimental Virology (LIV) and the German Center for Infection Research (DZIF).</li>
  </ul>
</div>
</div>
</article>
